Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2499${count})

  • Research Grant, 2020
    GBA Variations, Cholinergic Degeneration, and Cognitive Decline in Parkinson’s Disease

    Study Rationale:
    Mutations in the GBA gene are the most common genetic risk factors for Parkinson’s disease. People with GBA mutations (GBA-PD) may develop the disease at a younger age and may have...

  • Therapeutic Pipeline Program, 2019
    Identification of Novel Compounds that Improve Mitochondrial Quality Control

    Study Rationale:
    Dysfunction of mitochondria, the powerhouses of the cell, has been linked to degeneration in nerve cells in Parkinson’s disease. When mitochondria can’t function properly, cellular...

  • Therapeutic Pipeline Program, 2021
    Compounds that Enhance the Activity of GCase as a Treatment for Parkinson’s Disease

    Study Rationale:
    Beta-glucocerebrosidase (GCase), a protein that processes some of the key components of cell membranes, is required for normal brain function. Reduced activity of this protein...

  • Analysis of Patient-Reported Outcomes from Fox Insight, 2021
    Characterizing Impairment Trajectories in People with Parkinson’s Disease

    Study Rationale: 
    Little is known about what causes individuals with Parkinson’s disease (PD) to develop symptoms, much less the genetic and non-genetic factors that influence these changes. In most...

  • Analysis of Patient-Reported Outcomes from Fox Insight, 2021
    Exploring Environmental and Genetic Mediators of Progression in Parkinson’s Disease

    Study Rationale:
    We currently do not understand why some people with Parkinson’s disease (PD) have particularly severe symptoms, or symptoms that progress rapidly, compared to those who do not. This...

  • Therapeutic Pipeline Program, 2021
    Targeting Brain-specific Stearoyl-CoA-Desaturase 5 (SCD5) as a Treatment for Parkinson’s Disease

    Study Rationale:
    Previous studies have shown that fat molecules called unsaturated fatty acids regulate the harmful effects that alpha-synuclein have on neurons. This protein forms a key part of Lewy...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.